Sign up for our FREE Weekly Newsletter
Current Issue
Past Issue
News and Information for Medical Professionals
Search Diabetes In Control
 
 
Bookmark and Share | Print | Category | Home Previous | Next
This article originally posted 13 March, 2007 and appeared in  Issue 355
Pioglitazone Linked to Drug Interactions With Gemfibrozil, Rifampin
Te FDA approved safety labeling revisions for the antidiabetic agents pioglitazone and pioglitazone/metformin to warn of interactions associated with concomitant use of the pioglitazone component and drugs known to induce or inhibit the cytochrome P (CYP) 450 isoenzyme 2C8 (CYP 2C8).

The metabolism of pioglitazone involves multiple cytochrome P450 (CYP) isoforms, of which CYP 2C8 (and to lesser degrees, CYP 3A4 and CYP 1A1) have the highest activity. Use of a CYP 2C8 inhibitor (eg, gemfibrozil) may therefore significantly increase the area under the curve (AUC) of pioglitazone; use of a CYP 2C8 inducer (eg, rifampin) may cause a significant decrease.

In a clinical study of 10 healthy volunteers, the addition of oral gemfibrozil (600 mg twice daily) to pioglitazone (30 mg) yielded a 226% increase in pioglitazone exposure (AUC0-24) compared with pioglitazone alone.

A similar study (n = 10) showed that concomitant administration of oral rifampin (600 mg once daily) and pioglitazone (30 mg) resulted in a decrease in the AUC of pioglitazone by 54%.

The FDA notes that if an inhibitor or inducer of CYP 2C8 is started or stopped during treatment with pioglitazone, changes in diabetes treatment may be required based on clinical response.

Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Treatment with pioglitazone/metformin combination tablets is warranted for patients who are inadequately controlled with either component alone or already are receiving both.

Gemfibrozil tablets (Lopid, Pfizer Inc) are indicated as adjunctive therapy for the treatment of adult patients with types 4 and 5 hyperlipidemias who present a risk for pancreatitis and do not respond adequately to diet, and for reducing the risk for de novo coronary heart disease in type 2b patients with lipid abnormalities who have demonstrated inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (eg, bile acid sequestrants and nicotinic acid).
Rifampin capsules and injection (Rifadin and Rifadin IV, Sanofi-Aventis US) are indicated for use as part of a treatment regimen for tuberculosis and for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx.

We want to surpass our JDRF walk goal and we need your help. Please click the Sneaker and make a donation.

 

Bookmark and Share | Print | Category | Home

This article originally posted 13 March, 2007 and appeared in  Issue 355

Past five issues: Issue 495 | Issue 494 | Issue 493 | Issue 492 | Issue 491 |

Diabetes In Control Advertisers

Print This Week's Newsletter
Download This Week's Newsletter
Newsletter is in Adobe format
If you don't haveAdobe Acrobat Reader , you can download it for Free here .

Free CE Available
CE Programs On Diabetes Available here



Text Advertisement


Search Articles On Diabetes In Control
Sign up for our FREE Weekly Newsletter
Current Issue
Past Issue
Privacy / Advertising With Us / Contact Us
Add us to your favorite news reader
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.